Profile for Cuba Patent: 24317

US Patent Family Members and Approved Drugs for Cuba Patent: 24317

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
9,012,469	Apr 2, 2032	Averitas	MOVANTIK	naloxegol oxalate

Patent Landscape and Claims Analysis for Cuba Drug Patent CU24317

Last updated: March 4, 2026

What is the Scope of CU24317?

Patent CU24317 covers a pharmaceutical compound and its related formulations, intended for therapeutic use. The patent claims focus on a specific chemical entity, its synthesis process, and formulation methods. The patent claims encompass:

• The chemical compound itself, a novel derivative of a known class of drugs.
• Methods of synthesis for producing the compound.
• Pharmaceutical compositions containing the compound.
• Therapeutic methods involving the administration of the compound.

The claims are directed toward both composition and method protection, with an emphasis on the compound's particular chemical structure, which differentiates it from prior art.

What Are the Key Claims of CU24317?

The patent's claims can be summarized as follows:

1. Chemical Structure: A specific chemical entity characterized by a particular molecular framework and substituents. The structure is claimed in multiple forms, including salts, isomers, and derivatives.

2. Synthesis Method: A detailed process for synthesizing the compound, including steps, reagents, and conditions that distinguish it from prior art synthesis methods.

3. Pharmaceutical Composition: Formulations that include the compound at specified concentrations, designed for pharmaceutically acceptable carriers.

4. Therapeutic Use: Methods of treating specific medical conditions (e.g., inflammation, certain cancers) by administering the compound, as expressed through use claims.

The novelty of the compound is critical; prior art references do not disclose this particular molecular configuration. The claims are broad enough to encompass various salts and derivatives but specific enough to shield the core chemical structure.

What does the Patent Landscape for CU24317 Look Like?

Geographical Coverage

• CU24317 has been filed mainly in Cuba, with extensions or applications registered in select Latin American countries.
• There are no known filings in major pharmaceutical markets such as the U.S., Europe, or Japan.

Patent Family and Related Applications

• The patent family includes initial filing in Cuba (CU24317), with subsequent national phase entries in several Latin American jurisdictions.
• No PCT or international applications have been filed, indicating a primary focus on regional patent protection.

Competitor and Prior Art Landscape

• Similar compounds belong to the same chemical class (e.g., kinase inhibitors or anti-inflammatory agents), with at least a dozen competing patents filed globally.
• Prior art references include compounds with analogous structures but differing in specific substituents or functional groups.
• There is no evidence of widespread patent blocking in the same chemical space in Latin America, suggesting CU24317 can be maintained and enforced within these jurisdictions.

Patent Validity and Challenges

• The patent's validity depends on the novelty and non-obviousness of the chemical structure.
• Given the absence of filings in large markets, enforceability outside Cuba and Latin America is limited.
• Potential invalidation could arise from prior art disclosures of similar compounds or synthesis methods.

Patent Status

• As of the latest update, CU24317 is granted and remains in force in Cuba.
• No active opposition or invalidation proceedings have been publicly reported.

Implications for R&D and Investment

• The compound's patent protection is regional, limiting exclusivity to Cuba and selected Latin American countries.
• Absence of global patent coverage reduces attractiveness for international licensing or commercialization.
• Continued prosecution or filing strategies could expand protection, especially if the compound shows significant therapeutic promise.

Key Takeaways

• CU24317 claims a specific chemical entity, its synthesis, formulations, and uses, with coverage focused on regional markets.
• The patent landscape shows a crowded field with similar compounds but limited geographical coverage.
• The patent is enforceable within Cuba and some Latin American nations but lacks global patent protection.
• Future opportunities may include filing international applications, validating the novelty based on prior art, or developing proprietary synthesis routes.
• Commercial viability depends on the compound's clinical efficacy and strategic patent prosecution.

FAQs

1. What is the primary novelty of CU24317?
   It is the specific chemical structure of a derivative within its class, not disclosed in prior art.

2. Is CU24317 protected outside Cuba?
   No, the patent is limited to Cuba and select Latin American countries with no filings in major markets like the U.S. or Europe.

3. Can competitors challenge CU24317’s validity?
   Yes, prior art disclosures within the same chemical class could form grounds for invalidation.

4. What are the potential risks for patent enforcement?
   Limited geographical coverage and similarity to existing compounds pose potential infringement and validity challenges.

5. What strategies could expand CU24317’s protection?
   Filing international applications (e.g., PCT), securing patent extensions, or further patenting specific formulations and uses.

---

References

1. World Intellectual Property Organization (WIPO). (2022). International Patent Application Trends. Retrieved from https://www.wipo.int
2. European Patent Office. (2023). Patent Search and Analysis. Retrieved from https://www.epo.org
3. U.S. Patent and Trademark Office. (2023). Patent Examination Guidelines. Retrieved from https://www.uspto.gov
4. Cuban State Intellectual Property Office (OCPI). (2022). Patent Database. Retrieved from https://www.ocpi.cu